147 related articles for article (PubMed ID: 11307097)
21. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
22. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
Eccles SA; Box GM; Court WJ; Bone EA; Thomas W; Brown PD
Cancer Res; 1996 Jun; 56(12):2815-22. PubMed ID: 8665519
[TBL] [Abstract][Full Text] [Related]
23. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration.
Kajita M; Itoh Y; Chiba T; Mori H; Okada A; Kinoh H; Seiki M
J Cell Biol; 2001 May; 153(5):893-904. PubMed ID: 11381077
[TBL] [Abstract][Full Text] [Related]
24. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
Winding B; NicAmhlaoibh R; Misander H; Høegh-Andersen P; Andersen TL; Holst-Hansen C; Heegaard AM; Foged NT; Brünner N; Delaissé JM
Clin Cancer Res; 2002 Jun; 8(6):1932-9. PubMed ID: 12060638
[TBL] [Abstract][Full Text] [Related]
25. A clinical nude mouse metastatic model for highly malignant human pancreatic cancer.
An Z; Wang X; Kubota T; Moossa AR; Hoffman RM
Anticancer Res; 1996; 16(2):627-31. PubMed ID: 8687107
[TBL] [Abstract][Full Text] [Related]
26. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.
Davies B; Brown PD; East N; Crimmin MJ; Balkwill FR
Cancer Res; 1993 May; 53(9):2087-91. PubMed ID: 8347186
[TBL] [Abstract][Full Text] [Related]
27. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival.
Jones LE; Humphreys MJ; Campbell F; Neoptolemos JP; Boyd MT
Clin Cancer Res; 2004 Apr; 10(8):2832-45. PubMed ID: 15102692
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression.
Yamamoto H; Itoh F; Iku S; Adachi Y; Fukushima H; Sasaki S; Mukaiya M; Hirata K; Imai K
J Clin Oncol; 2001 Feb; 19(4):1118-27. PubMed ID: 11181677
[TBL] [Abstract][Full Text] [Related]
30. Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFNgamma-based cancer therapy in mice.
Van Roy M; Van Lint P; Van Laere I; Wielockx B; Wilson C; López-Otin C; Shapiro S; Libert C
Mol Cancer Ther; 2007 Sep; 6(9):2563-71. PubMed ID: 17876053
[TBL] [Abstract][Full Text] [Related]
31. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis.
Goss KJ; Brown PD; Matrisian LM
Int J Cancer; 1998 Nov; 78(5):629-35. PubMed ID: 9808534
[TBL] [Abstract][Full Text] [Related]
32. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
[TBL] [Abstract][Full Text] [Related]
33. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo.
Kapischke M; Fischer T; Tiessen K; Tschesche H; Bruch HP; Kalthoff H; Kruse ML
Int J Oncol; 2008 Jan; 32(1):273-82. PubMed ID: 18097568
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
Taraboletti G; Garofalo A; Belotti D; Drudis T; Borsotti P; Scanziani E; Brown PD; Giavazzi R
J Natl Cancer Inst; 1995 Feb; 87(4):293-8. PubMed ID: 7535861
[TBL] [Abstract][Full Text] [Related]
35. Batimastat (BB-94) inhibits matrix metalloproteinases of equine laminitis.
Pollitt CC; Pass MA; Pollitt S
Equine Vet J Suppl; 1998 Sep; (26):119-24. PubMed ID: 9932102
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
37. The matrix metalloproteinase inhibitor batimastat inhibits the lung colonisation of orthotopically implanted malignant pancreatic tumor cells in SCID mice.
Mirzaie M; Herse B; Oster O; Schöndube F
Swiss Surg; 2002; 8(4):165-70. PubMed ID: 12227109
[TBL] [Abstract][Full Text] [Related]
38. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
39. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.
Das A; McLamore A; Song W; McGuire PG
Arch Ophthalmol; 1999 Apr; 117(4):498-503. PubMed ID: 10206578
[TBL] [Abstract][Full Text] [Related]
40. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury.
Falk V; Soccal PM; Grünenfelder J; Hoyt G; Walther T; Robbins RC
Eur J Cardiothorac Surg; 2002 Jul; 22(1):53-8. PubMed ID: 12103373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
